An Overview of Cannabinoid Interactions With Common Pediatric Antineoplastic Agents
Pediatric Blood & Cancer · 2026-07 · 73 (7)
DOI: 10.1002/1545-5017.70336 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Pediatric Blood & Cancer, online erschienen am 29.04.2026. Verfasst von Shatila Zaman und 6 weiteren Autor:innen. Beteiligte Einrichtung: University of Michigan College of Pharmacy, Ann Arbor, Michigan, USA. Hauptthemen laut MEDLINE: Cannabinoids, Antineoplastic Agents, Neoplasms. Die Arbeit nennt 93 Literaturangaben.
Abstract (Originalsprache)
As interest in the use of cannabinoids for supportive care in pediatric cancers grows, there are emerging concerns about potential interactions with antineoplastic agents. This review provides an overview of potential drug–drug interactions between cannabinoids and 25 antineoplastic agents commonly used in pediatric hematology/oncology. Antineoplastic agents were stratified into low, medium, or high interaction risk based on the potential impact of cannabinoids on metabolic and/or pharmacodynamic pathways. The antineoplastic agents identified as high risk for interactions with cannabinoids included cyclophosphamide, doxorubicin, etoposide, ifosfamide, irinotecan, vinblastine, and vincristine. Key mechanisms of interaction include inhibition of cytochrome P450 enzymes and UDP‐glucuronosyltransferases and modulation of drug transporters such as P‐glycoprotein and breast cancer resistance protein. There is emerging evidence of a synergistic effect between cannabinoids and antineoplastic agents such as temozolomide, vinblastine, vinorelbine, and irinotecan. Pediatric patients exhibit developmental differences in drug metabolism and transporter expression, yet most pharmacokinetic data on cannabinoids are extrapolated from adult studies. There is a lack of pediatric‐specific safety, efficacy, and dosing data that underscores the need for age‐appropriate studies to ensure safe and effective integration of cannabinoids in pediatric cancer care.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- University of Michigan College of Pharmacy, Ann Arbor, Michigan, USA.
- Texas A&M College of Pharmacy, College Station, Texas, USA.
- Department of Pharmacy, Mayo Clinic, Rochester, New York, USA.
- Division of Pediatric Hematology/Oncology, Department of Pediatric and Adolescent Medicine, Mayo Clinic, Rochester, New York, USA.
- Department of Palliative Medicine, Mayo Clinic, Rochester, New York, USA.
ORCID-Profile: Alexis K Kuhn
Zitieren
APA
Zaman, S., Schatz, M., Kuhn, A. K., O'Keefe, M. B., Greenmyer, J. R., Smith, M. K., & Martin, C. E. (2026). An Overview of Cannabinoid Interactions With Common Pediatric Antineoplastic Agents. Pediatric Blood & Cancer, 73(7). https://doi.org/10.1002/1545-5017.70336
Vancouver
Zaman S, Schatz M, Kuhn AK, O'Keefe MB, Greenmyer JR, Smith MK, et al. An Overview of Cannabinoid Interactions With Common Pediatric Antineoplastic Agents. Pediatric Blood & Cancer. 2026;73(7). doi:10.1002/1545-5017.70336
BibTeX
@article{Zaman2026,
author = {Zaman, Shatila and Schatz, Mollie and Kuhn, Alexis K and O'Keefe, Madeleine B and Greenmyer, Jacob R and Smith, Melissa K and Martin, Catherine E},
title = {An Overview of Cannabinoid Interactions With Common Pediatric Antineoplastic Agents},
journal = {Pediatric Blood & Cancer},
year = {2026},
volume = {73},
number = {7},
doi = {10.1002/1545-5017.70336}
}
EUVIMED